BioAdaptives to Acquire Xycota Biosciences to Pursue the Potential of At Home Psilocybin Treatment
BioAdaptives, Inc. (OTCID:BDPT) has signed a definitive agreement to acquire Xycota Biosciences, LLC, a preclinical biotechnology company pursuing an ambitious goal: an oral psilocybin treatment that patients could take at home without hallucinogenic effects. The agreement, dated October 29, 2026, would bring Xycota's CNS drug-development programs into BioAdaptives. The transaction has not closed and remains subject to closing conditions. An...
Read more








